12,372 trials
Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With · Glucocorticoid-induced Osteoporosis
Primary: Change From Baseline in Lumbar Spine BMD Z-score as Assessed by Dual-energy X-ray Absorptiometry (DXA) at 12 Months — 0.23; 0.11 Z-score — p=0.68
Hereditary Angioedema
Primary: Time to Beginning of Symptom Relief Patient Global Impression of Change (PGI-C) — 1.61; 1.79; 6.72 Time (h) — p=<0.0001
Virus Diseases · Rabies
Primary: Number of Participants Reporting Serious Adverse Events (SAEs) After a Booster Dose of Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine — 2; 0; 3 Participants
Lung Cancer · Non-Small Cell Lung Cancer
Primary: Number of Non-HBV Participants Experiencing High Grade Treatment-Related Select Adverse Events — 2; 8; 5; 2 Participants
Major Depressive Disorder
Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 374; 437; 57 Participants
Surgery · Surgery--Complications · Perioperative/Postoperative Complications
Primary: Thirty-day Postoperative Mortality — 899; 866 Participants — p=0.41
Cardiovascular Disease · Hyperlipidemia
Primary: Change in Noncalcified Coronary Artery Plaque Volume (NCPV) — -45 mm^3
Head and Neck Squamous Cell Carcinoma
Primary: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) — 46.9…
Obesity
Primary: Mean Percent Change in Body Weight — -17.8; -22.7; -1.7 Percent change — p=<0.001
Adenocarcinoma of the Pancreas · Advanced Solid Tumors · Cancer
Primary: Determine if the Treatment of AMG 479 at 12 mg/kg and/or 20 mg/kg in Combination With Gemcitabine Improves Overall Survival as Compared With Placebo in Combination With…
Heart Failure
Primary: Number of Participants With Adverse Events — 111; 78 Participants
Diabetic Nephropathy
Primary: Percentage of Participants With 30% Decline in Estimated Glomerular Filtration Rate (eGFR) From Baseline at Week 104 — 18.2; 29.5 Percentage of Participants
Chronic Myelogenous Leukemia - Chronic Phase
Primary: Number of Participants With Adverse Events and Serious Adverse Events for Cohorts A and B up to 24 Weeks — 23; 26; 1; 3 Participants
Pain, Postoperative · Tonsillar Hypertrophy · Tonsillitis
Primary: Number of Participants With FLACC Pain Scores ≥7 From POD 1 Through POD 3 — 1; 1 participants
Gastrointestinal Disease
Primary: Consumption of Rescue Patient Controlled Propofol — 42.4; 28.6 mg